Skip to main content Skip to section navigation Skip to footer
OS Therapies, Inc.
  • About Us
  • Leadership
  • Technology
  • Angels
  • Trials
  • Investors
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact Us
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Jun 03, 2024 12:44 pm EDT

OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma

Sep 22, 2022 8:57 am EDT

Team Arnav Foundation Partners with OS Therapies Supporting the Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma

Jan 27, 2022 8:43 am EST

OS Therapies Announces Nationwide Open Enrollment of Remaining 36 to 42 Patients in Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma

Nov 03, 2021 8:57 am EDT

OS Therapies Receives Rare Pediatric Disease Designation (RDD) in Osteosarcoma for OST-HER2 (Listeria monocytogenes)

Oct 22, 2021 8:33 am EDT

OS Therapies Announces Dosing of First Patient in a Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma

Jun 23, 2021 8:44 am EDT

Children's Cancer Research Fund Supports AOST-2121 PhIIb Clinical Trial in Recurred, Resected Osteosarcoma

Apr 20, 2021 8:33 am EDT

OS Therapies Completes $6 Million Series A Funding Round

Jan 26, 2021 8:49 am EST

OS Therapies Receives Trial Approval From Children's Oncology Group for AOST2121 / OST31-164-01 An Open-Label Phase 2 Study of Maintenance Therapy With OST31-164 After Resection of Recurrent Osteosarcoma

Nov 17, 2020 8:37 am EST

OS Therapies Acquires All Indications for OST-HER2 (Listeria monocytogenes) in Solid Tumors, Including Canines

Oct 15, 2020 8:56 am EDT

FDA Transfers Investigational New Drug (IND) Application OST-HER2 (Listeria monocytogenes) to OS Therapies in Record Time - Phase IIb Trial in Osteosarcoma in Early 2021

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
OS Therapies, Inc.
©2026 OS Therapies, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap